Investors

Financial Calendar and Events

Upcoming events

DATE

EVENT

30 June 2018

Half year end

Mid-September 2018

Half year results announcement

Past events

DATE

EVENT

5 June 2018

Annual General Meeting

17 April 2018

Full year results announcement

15 March 2018

Trading Update announcement of in-licence agreement for novel gene therapy treatment

31 December 2017

Full year end

9 October 2017

Completion of placing to raise €15m

4 September 2017

Half year results

30 June 2017

Half year end

25 May 2017

Annual General Meeting

30 March 2017

Full year results announcement

28 March 2017

Commencement of EASE study, a Phase III Clinical Trial of AP101, Amryt Pharma’s lead drug candidate, which offers a potential treatment for Epidermolysis bullosa (EB)

31 December 2016

Full year end

5 December 2016

In-license agreement – in-licensing of Lojuxta® (lomitapide), a treatment for Homozygous Familial Hypercholesterolemia (HoFH)

2 December 2016

€20m facility agreed with European Investment Bank

13 September 2016

Half year results

7 July 2016

Annual General Meeting

30 June 2016

Half year end

9 June 2016

Financial results for the nine months to 31 December 2015

19 April 2016

Admission to trading on AIM and ESM